ArticleCancer discovery2017
Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer discovery, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 248 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
248citing papers in PubMed, 1 pooled it
29.4field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
248 citing papers in PubMed, 1 synthesis or guideline pooled it, 389 citations in OpenAlex.
- Meta-analyses of mouse and human prostate single-cell transcriptomes reveal widespread epithelial plasticity in tissue regression, regeneration, and cancer.Genome medicine · 2025Pooled it
- A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2024Trial
- Circulating tumor DNA profile recognizes transformation to castration-resistant neuroendocrine prostate cancer.The Journal of clinical investigation · 2020Trial
- Cabazitaxel plus carboplatin for the treatment of men with metastatic castration-resistant prostate cancers: a randomised, open-label, phase 1-2 trial.The Lancet. Oncology · 2019Trial
- Reframing cancer therapy through tumor plasticity.Nature cancer · 2026Review
- Neuromedin U 'innervation' reprograms myeloid immunosuppression in neuroendocrine prostate cancer.Oncogene · 2026Article
- Epigenetic reprogramming of lineage switching in cancer.FEBS letters · 2026Review
- Dual Functions of B7-H3-MAPK Signaling Orchestrate Tumor Immunosuppression via Regulating the Plasticity of Myeloid-derived Suppressor Cells and Fibroblasts.Cancer discovery · 2026Article
- A forward genetic screen identifies Sirtuin1 as a driver of neuroendocrine prostate cancer.The Journal of experimental medicine · 2026Article
- Tumour endothelial cell reprogramming orchestrates angiocrine signalling to drive chemoresistance in breast cancer.Angiogenesis · 2026Article
- Mapping prostate cancer pathobiology: A review of genetically engineered mouse models (GEMMs).Gene · 2026Review
- Recurrent intra-tumour heterogeneity is a hallmark of metastatic prostate cancer.Nature communications · 2026Article
- Targeting arginine metabolism overcomes chemotherapy resistance in aggressive-variant prostate cancers.iScience · 2026Article
- Cancer stem cell plasticity in shaping drug resistance landscapes in prostate cancer.Journal of advanced research · 2026Review
- Integrated single-cell and spatial transcriptomic profiling decodes lineage plasticity and immune microenvironment remodeling in prostate cancer progression.Molecular cancer · 2026Article
- EZH2 Suppression Diversifies Prostate Cancer Lineage Variant Evolution and Lacks Efficacy in Inhibiting Disease Progression.Cancer research · 2026Article
- Genetic and epigenetic mechanisms underlying treatment-induced neuroendocrine prostate cancer.Journal of the National Cancer Center · 2026Review
- PSMA PET-directed radiotherapy for prostate cancer: From precision planning to future innovations.View (Beijing, China) · 2026Article
- Epigenomics-guided precision oncology: Chromatin variants in prostate tumor evolution.International journal of cancer · 2026Review
- Expression of endogenous retroviral elements is associated with extracellular matrix remodeling in prostate cancer.Mobile DNA · 2026Article
188 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
13 authors at 2 institutions in 1 country.
Min ZouDepartments of Medicine and Urology, Institute of Cancer Genetics, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York.
Roxanne ToivanenDepartments of Medicine and Genetics and Developmental Biology, Institute of Cancer Genetics, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York.
Antonina MitrofanovaDepartment of Systems Biology, Columbia University Medical Center, New York, New York; and Department of Health Informatics, Rutgers, The State University of New Jersey, Newark, New Jersey.
Nicolas FlochDepartment of Urology, Columbia University Medical Center, New York, New York.
Sheida HayatiDepartment of Health Informatics, Rutgers, The State University of New Jersey, Newark, New Jersey.
Yanping SunDepartment of Medicine, Columbia University Medical Center, New York, New York.
Clémentine Le MagnenDepartments of Medicine and Urology, Institute of Cancer Genetics, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York.
Daniel ChesterDepartment of Urology, Columbia University Medical Center, New York, New York.
Elahe A MostaghelClinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
Andrea CalifanoDepartments of Systems Biology, Biomedical Informatics, and Biochemistry and Molecular Biophysics, Center for Computational Biology and Bioinformatics, Institute of Cancer Genetics, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York.
Mark A RubinEnglander Institute for Precision Medicine and Department of Pathology and Laboratory Medicine, Weil Cornell Medical College and New York-Presbyterian Hospital, New York, New York.
Michael M ShenDepartments of Medicine, Genetics and Development, Urology, and Systems Biology, Institute of Cancer Genetics, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York. cabateshen@columbia.edu mshen@columbia.edu.
Cory Abate-ShenDepartments of Urology, Medicine, Systems Biology, and Pathology and Cell Biology, Institute of Cancer Genetics, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, New York. cabateshen@columbia.edu mshen@columbia.edu.
Columbia University Irving Medical Center · USFred Hutch Cancer Center · US
Funding
Tumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Parisa Tehranifar · 1985 to 2026
$115.3MClinical and Translational Science AwardUL1TR001873 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI REILLY, MUREDACH P · 2016 to 2025
$99.0MTRANSCRIPTOME AND PROTEOME STRATIFICATION OF PROSTATE ADENOCARCINOMA PHENOTYPESP50CA097186 · NCI · FRED HUTCHINSON CANCER RESEARCH CENTER · PI John Kyung Lee · 2002 to 2026
$58.1MClinical and Translational Science AwardUL1TR000040 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GINSBERG, HENRY N · 2012 to 2015
$26.2MSteroid Metabolism in Castration-Resistant Prostate CancerP01CA163227 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Henry W. Long · 2013 to 2026
$25.0MPredicting Cancer Cell Response to Endogenous and Exogenous Perturbations at the Single Cell LevelR35CA197745 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ANDREA CALIFANO · 2015 to 2026
$11.5MSystematic pharmacological targeting of the core mechanisms responsible for maintaining cancer cell stateU54CA209997 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CALIFANO, ANDREA, HONIG, BARRY H · 2016 to 2021
$10.9MRoles for Nkx3.1 in Prostate Cancer InitiationP01CA154293 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI SHEN, MICHAEL M. · 2011 to 2015
$6.5MPreclinical analyses of advanced prostate cancer in genetically-engineered miceR01CA173481 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI Cory Abate-Shen · 2013 to 2026
$6.1MMolecular mechanisms of prostate cancer metastasisR01CA183929 · NCI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ABATE-SHEN, CORY · 2015 to 2025
$4.1MProgenitor cells of the mouse prostate epitheliumR01DK076602 · NIDDK · UNIV OF MED/DENT NJ-R W JOHNSON MED SCH · PI SHEN, MICHAEL M. · 2006 to 2016
$3.9MHigh-performance compute cluster for biomedical computingS10OD012351 · OD · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CALIFANO, ANDREA · 2012 to 2012
$2.0MNCATS NIH HHS UL1 TR000040NCATS NIH HHS UL1 TR001873NCI NIH HHS P01 CA154293NCI NIH HHS P01 CA163227NCI NIH HHS P30 CA013696NCI NIH HHS P50 CA097186NCI NIH HHS R01 CA173481NCI NIH HHS R01 CA183929NCI NIH HHS R01 CA196662NCI NIH HHS R35 CA197745NCI NIH HHS U54 CA209997NIDDK NIH HHS R01 DK076602NIH HHS S10 OD012351NIH HHS S10 OD021764
Abstract
Current treatments for castration-resistant prostate cancer (CRPC) that target androgen receptor (AR) signaling improve patient survival, yet ultimately fail. Here, we provide novel insights into treatment response for the antiandrogen abiraterone by analyses of a genetically engineered mouse (GEM) model with combined inactivation of
Indexed as
AndrostenesAnimalsCell Line, TumorCell TransdifferentiationDisease Models, AnimalDrug Resistance, NeoplasmGene Expression Regulation, NeoplasticHumansMaleMiceNeuroendocrine TumorsNeuronsProstatic Neoplasms, Castration-ResistantPTEN PhosphohydrolaseReceptors, AndrogenSignal TransductionabirateroneAndrostenesPTEN PhosphohydrolasePten protein, mouseReceptors, AndrogenSox11 protein, mouseSOXC Transcription FactorsTumor Suppressor Protein p53
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.